

Quarterly Report – June 2026

Perth, Australia; 13 July 2026: Regenerative medicine company Orthocell Limited (ASX: OCC, “Orthocell” or the “Company”) is pleased to release its Quarterly Report for the quarter ended 30 June 2026.

Key highlights for the quarter are as follows:

1. Record revenue of \$3.8 million for the June quarter and record revenue of \$13.2 million for FY2026, driven by continued adoption of Remplir™ in Australia and accelerating commercial traction in the United States and new international markets.

- June quarter revenue rose 20% on the March quarter to a new quarterly record of \$3.8 million, up 36% on the corresponding quarter (Q4 FY2025) last year.
- FY2026 revenue increased by 44% from the previous financial year to a new full-year record of \$13.2 million, underpinned by strong global growth in Remplir™ and Striate+™ sales.
- The June quarter marks Orthocell's highest quarterly revenue ever and continues a three-year trajectory of consistent commercial growth, with quarterly revenue increasing at a compound growth rate (CQGR) of 10% over the last 10 quarters.
- Total international revenue from Remplir sales now accounts for over 9% of total quarterly revenue and will continue to expand in the coming quarters. The Company is now targeting faster growth, with distributors appointed in Canada and Thailand, and sales expected to commence in the UK/EU in the first half of CY2027.
- U.S. Remplir sales generated \$0.33 million during the quarter, representing a 10% increase over the March quarter, with continued surgeon adoption and hospital approvals providing a strong foundation for expected revenue acceleration during FY2027.
- With its initial commercial distribution platform now established in the United States, Orthocell expects continued expansion in hospital adoption and surgeon utilisation, positioning the business for a material uplift in U.S. revenue as commercial penetration builds and second usage among surgeons begins to emerge.

2. Orthocell maintains a strong financial position with robust funds available of \$44.1 million¹ as at 30 June 2026 and is well-positioned for continued commercial expansion:

- As of 30 June 2026, funds available were \$44.1 million, providing a strong liquidity position. Based on current operating expenditure levels and existing strategic plans, the Company's cash reserves are more than adequate to fund ongoing U.S. commercialisation

¹ AU\$44.1M as of 30 June 2026, this includes \$9.4 million in cash and cash equivalents and \$34.7 million in security and term deposits with maturities ranging from 3 to 12 months.

activities, regulatory initiatives, manufacturing scale-up programs, and the advancement of strategic growth opportunities, with no further funding required.

- Orthocell remains focused on growing revenue, expanding manufacturing facility capacity, optimising production efficiencies, and disciplined cost management. Together, these priorities support the Company's continued progress towards cash flow breakeven and the ongoing commercialisation of its regenerative medical product portfolio globally.

3. Commercialisation of Remplir in the US continues to track ahead of expectations, with all key commercial metrics demonstrating strong growth. Highlights include:

- Distributor network expanding, providing coverage across approximately 50% of the U.S. population.
- Value Analysis Committee (VAC) approvals increased 38% during the quarter to 44, expanding Remplir's access to 151 hospitals, with a further 64 applications progressing through the approval process.
- Approval received for Remplir across the U.S. Department of Defense (DoD) and Veterans Affairs (VA) healthcare networks, providing access to 221 military and veterans' medical centres
- Hospital adoption continued to accelerate, with 70 hospitals now purchasing Remplir (up 27% during the quarter), while the number of surgeons using the product increased 55% to 76 in the June quarter. Unit sales totalled 119 units.
- Completion of 9 medical education events, including regional, national and journal club meetings across key U.S. states, introducing surgeons to Remplir's advanced nerve repair capabilities and the clinical evidence supporting improved surgical workflow and patient outcomes.

4. Remplir global humanitarian reach expanded through a coordinated philanthropic initiative delivering advanced nerve repair technology to victims of war in Ukraine

- Additional Remplir devices are being shipped to Ukraine to support the treatment of complex battlefield and civilian trauma injuries via philanthropic support and coordination through The Ukraine Crisis Appeal.
- The deployment of Remplir in a real-world conflict environment highlights the product's portability, ease of use, and suitability for treating complex peripheral nerve injuries in major trauma settings. Further humanitarian strategies are underway, and this will be undertaken on a commercial basis where areas of humanitarian need are delivered by NGO's.

5. Remplir United Kingdom / EU US\$750 million market² access program progressing according to schedule:

- Following Orthocell's regulatory submission to the British Standards Institution (BSI) in December 2025 to support approval for commercial distribution of Remplir in the UK and EU, the process remains on track, with regulatory approval anticipated by the end of CY2026.
- Continued development with KOLs and LEDA Orthopaedics, our UK distributor, was undertaken during the quarter, including onboarding key account personnel, training representatives, and preparing launch activities ahead of expected regulatory clearance.

6. Remplir nerve-sparing prostate cancer surgery commercial opportunity gathers momentum:

- Over 250 procedures have now been performed by 39 surgeons across Australia's five most populous states for a new indication, presenting a significant opportunity to expand the Remplir Total Addressable Market in the U.S. from U.S.\$1.6 billion to approximately U.S.\$2 billion².
- Initial clinical performance data from nerve-sparing procedures using Remplir is currently being compiled. Given that robust evaluation of patient outcomes in the setting requires a 12-month post-procedure follow-up, the Company is prioritising data integrity and clinical rigour over premature disclosure. Release of the data has been agreed to follow the publication of the surgeon-led academic paper, with an announcement anticipated in 2H CY2026.
- Encouraged by strong surgeon uptake and positive clinical feedback, Orthocell has committed to additional clinical research investment to build on this early success and support the planned U.S. market expansion of Remplir in prostate surgeries. No additional FDA approvals are required for this indication.

7. Continued global roll out of Striate™ via Orthocell's global distribution partner BioHorizons, with Colombia and Ecuador regulatory approval received in the quarter

- Orthocell received regulatory approval from the Colombian Health Authority (National Institute for Drug and Food Surveillance (INVIMA)) and the Ecuadorian Health Authority (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria (ARCSA)), enabling the Company to commence sales of its market-leading dental guided bone regeneration product, Striate+, in Colombia and Ecuador.
- Orthocell is working with its exclusive global distribution partner, BioHorizons, on initial market launches in Brazil, Colombia and Ecuador and expects to commence commercial distribution in 2H CY2026. As Striate+ and Remplir are both derived from Orthocell's proprietary collagen platform, continued growth in Striate+ sales supports and underpins the manufacturing scale-up of Remplir, delivering shared production efficiencies across the Company's product portfolio.

² Nerve repair market sizes estimated using referenced papers from both US and OUS databases and studies.

Orthocell CEO and MD, Paul Anderson, said: “Our record FY2026 results reflect the successful execution of Orthocell Limited’s global commercialisation strategy, with strong momentum across Australia and early scale-up in the United States. U.S. surgeon adoption and hospital engagement continue to build, and we expect this to be a key driver of revenue growth as our distribution footprint expands.


Looking ahead, we are entering a significant near-term catalyst phase. In the United States, we expect continued growth in procedural adoption and hospital penetration as our commercial platform matures. In parallel, we are progressing toward anticipated regulatory approval for Remplir in the UK and EU, which will unlock one of the largest peripheral nerve repair markets globally.

During the quarter, we also commenced the U.S. regulatory program for a tendon repair application based on our collagen technology platform. This represents a natural extension of our regenerative medicine portfolio, leveraging our existing manufacturing capability and commercial infrastructure to address a significant unmet clinical need. Importantly, it expands our addressable market through a complementary product offering for our existing surgeon customer base.”

Corporate and Financial Commentary

Orthocell reported record quarterly revenue of \$3.8 million for the June 2026 quarter, an increase of 20% on the March quarter (Figure 1). FY2026 revenue reached a record \$13.2 million, up 44% on the previous financial year, driven by strong growth in Australian Remplir sales and increasing U.S. commercial sales. The Company's consistent revenue growth, reflected in a compound quarterly growth rate (CQGR) of 10% over the past 10 quarters, demonstrates increasing adoption by both new and existing surgeons, driving higher sales of Orthocell's market-leading products. The Company expects to achieve a higher growth rate in the 2026/2027 year.

Figure 1: Quarterly Revenue Growth



1. Revenue includes product sales, sundry, licensing, grant and interest income (excludes R&D tax refund recorded as income)

2. Excluding US Remplir Sales where applicable.

Cash receipts from customers, inclusive of GST, totalled \$2.5 million for the quarter, compared to \$1.6 million in the prior quarter from previous growth in quarterly revenues. Net operating cash flows resulted in a cash burn of \$3.6 million, compared to a \$0.1 million inflow in the prior quarter, largely due to the non-recurrence of a \$3.0 million R&D tax refund received in March. After adjusting for the R&D tax incentive and non-recurring expenditure, normalised operating cash burn was broadly stable at \$2.4 million, compared to \$2.5 million in the prior quarter.

Expenditure during the quarter continued to focus on commercial execution and research and development activities supporting the Company's portfolio of regenerative medicine products, finalisation of the NetSuite finance system, and expansion activities that will continue into FY2027.

At 30 June 2026, Orthocell had funds available of \$44.1 million, providing a strong liquidity position. Based on current operating expenditure levels and existing strategic plans, the Company's cash reserves are more than adequate to take it into future profit without any further need for funding. Orthocell remains well-funded to continue commercialising its portfolio of regenerative medical products. Continued revenue growth from established markets in Australia and Singapore, along with continued sales growth in the US, highlights the best-in-class product dynamic and the significant revenue potential of global markets.

As detailed in Section 6.1 of Appendix 4C, payments to related parties include salaries, fees and superannuation contributions.

Release authorised by:

Paul Anderson

Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson

Orthocell Limited
CEO and MD

P: +61 8 9360 2888

E: paul.anderson@orthocell.com

Media enquiries

Haley Chartres

H^CK Director

P: +61 423 139 163

E: haley@hck.digital

Investor enquiries

Shaun Duffy

VECTOR Advisors

P: +61 404 094 384

E: sduffy@vectoradvisors.au

About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Name of entity

Orthocell limited

ABN

57 118 897 135

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows		Current quarter \$A'000s	Year to date (12 months) \$A'000s
1. Cash flows from operating activities			
1.1 Receipts from customers		2,459	7,649
1.2 Payments for:			-
(a) research & development (including allocated staff costs)		(1,267)	(5,388)
(b) product manufacturing and operating overheads		(1,595)	(5,500)
(c) marketing, business development & investor relations		(1,945)	(6,750)
(d) leased assets		(1)	(4)
(e) staff costs (other than R&D staff)		(890)	(4,319)
(f) administration & corporate costs		(929)	(3,320)
1.3 Dividends received (see note 3)		-	-
1.4 Interest received		484	1,908
1.5 Interest & other costs of finance paid		-	(14)
1.6 Income taxes paid		-	-
1.7 Government grants & tax incentives received		-	30
1.8 Other (R&D tax incentive rebate)		-	2,998
1.9 Net cash from / (used in) operating activities		(3,684)	(12,710)
2. Cash flows from investing activities			
2.1 Payments to acquire:			
(a) entities		-	-
(b) businesses		-	(1,005)
(c) property, plant & equipment		(1,043)	(1,330)
(d) investments		-	(42,000)
(e) intellectual property		-	-
(f) other non-current assets		-	-
2.2 Proceeds from disposal of:			
(a) entities		-	-
(b) businesses		-	-
(c) property, plant & equipment		-	-
(d) investments		5,500	7,300
(e) intellectual property		-	-
(f) other non-current assets		-	-
2.3 Cash flows from loans to other entities		-	-
2.4 Dividends received (see note 3)		-	-
2.5 Other (provide details if material)		-	-
2.6 Net cash from (used in) investing activities		4,457	(37,035)

Appendix 4C

Quarterly Report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000s	Year to date (12 months)
3. Cash flows from financing activities			
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	-	30,000	-
3.2 Proceeds from issue of convertible debt securities	-	-	-
3.3 Proceeds from exercise of share options	300	1,799	-
3.4 Transaction costs related to issues of equity securities, or convertible notes	-	(1,500)	-
3.5 Proceeds from borrowings	578	578	-
3.6 Repayment of borrowings	-	-	-
3.7 Transaction costs related to loans & borrowings	-	-	-
3.8 Dividends paid	-	-	-
3.9 Other (lease payments)	(95)	(363)	-
3.10 Net cash from / (used in) financing activities	783	30,514	

4. Net increase / (decrease) in cash & cash equivalents for the period		
4.1 Cash & cash equivalents at beginning of period	7,833	28,620
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(3,684)	(12,710)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	4,457	(37,035)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	783	30,514
4.5 Effect of movement in exchange rates on cash held	-	-
4.6 Cash & cash equivalents at end of period*	9,389	9,389

5. Reconciliation of cash & cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000s	Previous quarter \$A'000s
5.1 Bank balances	5,030	5,349
5.2 Term deposits	4,359	2,484
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
5.5 Cash & cash equivalents at the end of the quarter (should equal item 4.6 above)*	9,389	7,833

6. Payments to related parties of the entity & their associates	Current quarter \$A'000s
6.1 Aggregate amount of payments to these parties included in item 1	335
6.2 Aggregate amount of payments to these parties included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments</i>	

7. Financing facilities available <i>Note: the term 'facility' includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the position.</i>	Total facility amount at quarter end \$A'000s	Amount drawn at quarter end \$A'000s
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	578	578
7.4 Total financing facilities	578	578

7.5 Unused financing facilities available at quarter end	-
---	---

Appendix 4C

Quarterly Report for entities subject to Listing Rule 4.7B

- 7.6 Include in the box below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

The Company has a premium funding facility with Westpac Banking Corporation to finance annual insurance premiums. The facility carries a flat rate of 3.3% p.a.

8. Estimated cash available for future operating activities	\$A'000s
8.1 Net cash from / (used in) operating activities (item 1.9)	(3,684)
8.2 Cash and cash equivalents at quarter end (item 4.6)	9,389
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)*	9,389
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	3

Note: if the entity has reported positive net operating cash flows in item 1.9 answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5

- 8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being

Answer: N/A - *In addition to cash and cash equivalents of \$9,389k, the Company held \$34,700k of term deposits maturing within 12 months at 30 June 2026. These balances are not included within cash and cash equivalents in accordance with AASB 107.

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful.

Answer: N/A

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Compliance statement

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- This statement gives a true and fair view of the matters disclosed.

Date: 13 July 2026

Authorised by: Board of Orthocell Limited

(Name of body or officer authorising release - see note 4)

Notes

- This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
- If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.